123 related articles for article (PubMed ID: 18057705)
1. Population pharmacokinetics and proton pump inhibitory effects of intravenous lansoprazole in healthy Japanese males.
Sakurai Y; Hirayama M; Hashimoto M; Tanaka T; Hasegawa S; Irie S; Ashida K; Kayano Y; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2007 Dec; 30(12):2238-43. PubMed ID: 18057705
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
Klotz U
Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
[TBL] [Abstract][Full Text] [Related]
3. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.
Hunfeld NG; Mathot RA; Touw DJ; van Schaik RH; Mulder PG; Franck PF; Kuipers EJ; Geus WP
Br J Clin Pharmacol; 2008 May; 65(5):752-60. PubMed ID: 18241283
[TBL] [Abstract][Full Text] [Related]
4. Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h.
Howden CW; Metz DC; Hunt B; Vakily M; Kukulka M; Amer F; Samra N
Aliment Pharmacol Ther; 2006 Apr; 23(7):975-84. PubMed ID: 16573800
[TBL] [Abstract][Full Text] [Related]
5. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
[TBL] [Abstract][Full Text] [Related]
6. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
Furuta T; Shirai N; Xiao F; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2001 Nov; 70(5):484-92. PubMed ID: 11719736
[TBL] [Abstract][Full Text] [Related]
7. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Eur J Clin Pharmacol; 2004 Nov; 60(9):623-8. PubMed ID: 15448955
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of proton pump inhibitors in children.
Litalien C; Théorêt Y; Faure C
Clin Pharmacokinet; 2005; 44(5):441-66. PubMed ID: 15871633
[TBL] [Abstract][Full Text] [Related]
10. [13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole.
Furuta T; Kodaira C; Nishino M; Yamade M; Sugimoto M; Ikuma M; Hishida A; Watanabe H; Umemura K
Aliment Pharmacol Ther; 2009 Aug; 30(3):294-300. PubMed ID: 19459830
[TBL] [Abstract][Full Text] [Related]
11. The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects.
Xu HR; Chen WL; Li XN; Chu NN
Pharm Biol; 2010 Aug; 48(8):947-52. PubMed ID: 20673183
[TBL] [Abstract][Full Text] [Related]
12. CYP2C19-guided design of a proton pump inhibitor dose regimen to avoid the need for pharmacogenetic individualization in H. pylori eradication.
Ward MB; Foster DJ
Eur J Clin Pharmacol; 2011 Mar; 67(3):261-6. PubMed ID: 21079935
[TBL] [Abstract][Full Text] [Related]
13. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
Itagaki F; Homma M; Yuzawa K; Nishimura M; Naito S; Ueda N; Ohkohchi N; Kohda Y
J Pharm Pharmacol; 2004 Aug; 56(8):1055-9. PubMed ID: 15285851
[TBL] [Abstract][Full Text] [Related]
14. Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages.
Metz DC; Amer F; Hunt B; Vakily M; Kukulka MJ; Samra N
Aliment Pharmacol Ther; 2006 Apr; 23(7):985-95. PubMed ID: 16573801
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects.
Zhang D; Zhang Y; Liu M; Wang X; Yang M; Han J; Liu H
Eur J Drug Metab Pharmacokinet; 2013 Sep; 38(3):209-15. PubMed ID: 23229306
[TBL] [Abstract][Full Text] [Related]
16. CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers.
Gawrońska-Szklarz B; Adamiak-Giera U; Wyska E; Kurzawski M; Gornik W; Kaldonska M; Drozdzik M
Eur J Clin Pharmacol; 2012 Sep; 68(9):1267-74. PubMed ID: 22418828
[TBL] [Abstract][Full Text] [Related]
17. Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status.
Furuta T; Shirai N; Sugimoto M; Nakamura A; Okudaira K; Kajimura M; Hishida A
Aliment Pharmacol Ther; 2005 Jul; 22(1):67-74. PubMed ID: 15963082
[TBL] [Abstract][Full Text] [Related]
18. Stronger inhibition of gastric acid secretion by lafutidine, a novel H2 receptor antagonist, than by the proton pump inhibitor lansoprazole.
Yamagishi H; Koike T; Ohara S; Horii T; Kikuchi R; Kobayashi S; Abe Y; Iijima K; Imatani A; Suzuki K; Hishinuma T; Goto J; Shimosegawa T
World J Gastroenterol; 2008 Apr; 14(15):2406-10. PubMed ID: 18416470
[TBL] [Abstract][Full Text] [Related]
19. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients.
Miura M; Inoue K; Kagaya H; Satoh S; Tada H; Sagae Y; Habuchi T; Suzuki T
Biopharm Drug Dispos; 2007 May; 28(4):167-75. PubMed ID: 17377957
[TBL] [Abstract][Full Text] [Related]
20. Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole.
Cho H; Choi MK; Cho DY; Yeo CW; Jeong HE; Shon JH; Lee JY; Shin JS; Cho M; Kim DY; Shin JG
J Clin Pharmacol; 2012 Jul; 52(7):976-84. PubMed ID: 21593280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]